Storia in 1 fonti

Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trial

Zydus Lifesciences said its drug Saroglitazar Magnesium met the primary goal of a global Phase II(b) trial for MASH, a serious liver disease linked to metabolic disorders.

Raccontata da

economictimes.indiatimes.com

Timeline cronologica

lunedì 31 agosto 2026·economictimes.indiatimes.com
Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trial
Zydus Lifesciences said its drug Saroglitazar Magnesium met the primary goal of a global Phase II(b) trial for MASH, a serious liver disease linked to metabolic disorders.